Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Micromet Presents Update At ASCO 2009 On A Phase 1b Combination Study Of Adecatumumab And Docetaxel
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida, USA(1).
generic viagra online
In 'Reading' A Gaze, What We Believe Changes What We See
In primates including ourselves, the ability to register where others are looking is key in social circles. And, according to a new report published online on June 25th in Current Biology, a Cell Press publication, the way our brains process gaze-direction is much more sophisticated than a simple eyes-right versus eyes-left.
News of the day
Condoms Associated With Moderate Protection Against Herpes Simplex Virus 2
Condom use is associated with a reduced risk of contracting herpes simplex virus 2, according to a report based on pooled analysis of data from previous studies in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Sexual Health

Medimix International To Exhibit At American Society of Clinical Oncology AGM

Medimix International, a leader in global healthcare marketing research for life sciences industry, announced that it will be exhibiting at the 45th AGM of the American Society of Clinical Oncology, which will take place in Orlando, Florida from May 29-June 2, 2009. The annual ASCO meeting is considered to be the premier educational and scientific event in the oncology community, a forum for cutting-edge scientific and educational developments in oncology with a focus on personalizing cancer care. Medimix International has a long history of working in the field of oncology/hematology, one of its key therapeutic areas, and in fact around 35-40% of its yearly projects are conducted in that field. It currently manages a panel of more than 17,000 oncologists and over 13,000 hematologists from North America, Europe, Asia, Latin America, and the Middle East. Specialties included in the panel are medical, radiation, surgical, gynecology, and pediatric oncology, with Medimix"s demonstrating particular expertise in the areas of anemia, breast, lung, bowel, prostate, and renal cancers. "Oncology is a very challenging field where treatment options are continuously evolving," commented Dr. Tessa Schoor, Medimix"s Chief Medical Officer. "It is crucial for us to stay up to date on the new therapeutic outcomes that are discussed at the ASCO meeting every year. " With over 26,000 professionals from 128 countries attending the ASCO event, Medimix"s presence will have a dual purpose: to extend an invitation to these experts to become part of its new online community and to showcase its services to clients in the pharmaceutical, medical device and biotechnology fields. "Over 53% of visitors at ASCO come from outside the United States," noted Henry Gazay, CEO of Medimix International. "The reach of our onco/hematology panel being global, exhibiting at ASCO represents a unique opportunity to meet some of the key members of our community from diverse countries around the world. Physicians and KOLs will come to our booth to share their experience of working with us and working together. It is also a great opportunity to show new marketing services to our clients." Medimix International will be present at the ASCO exhibition, May 29- June 1, booth #426 Medimix International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009